Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs

Regulatory Peptides

Volumn 173, Issue 1-3, 2012, Pages 74-81

  Cai, Yongming ^a,b   Zhang, Zongpeng ^b   Fan, Kai ^c   Zhang, Jun ^d   Shen, Wenjin ^b   Li, Ming ^b   Si, Duanyun ^b   Luo, Hua ^c   Zeng, Yong ^b   Fu, Peng ^b   Liu, Changxiao ^b  

^a TIANJIN UNIVERSITY   (China)

^b TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^c Chongqing Fujin Biomedical Company Ltd   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Antiviral activity; Distribution; Excretion; IFN SA; PEG IFN SA; Pharmacokinetics

Indexed keywords

ANTIVIRUS AGENT; CONSENSUS INTERFERON; PEGYLATED RECOMBINANT CONSENSUS INTERFERON ALPHA VARIANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; GUINEA PIG; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RHESUS MONKEY; SINGLE DRUG DOSE; SPECIES COMPARISON; TISSUE DISTRIBUTION; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; BILE; CELL SURVIVAL; CELLS, CULTURED; FECES; FEMALE; GUINEA PIGS; HUMANS; INTERFERON-ALPHA; MACACA FASCICULARIS; MACACA MULATTA; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; VESICULOVIRUS;

CAVIA; MACACA FASCICULARIS; MACACA MULATTA; RATTUS;

EID: 83255193974     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.09.008     Document Type: Article

References (39)

1. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264.
2. Xu D., Erickson S., Szeps M., Gruber A., Sangfelt O., Einhorn S., Pisa P., Grander D. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000, 96:4313-4318.
3. Ceaglio N., Etcheverrigaray M., Conradt H.S., Grammel N., Kratje R., Oggero M. Highly glycosylated human alpha interferon: an insight into a new therapeutic candidate. J Biotechnol 2010, 146:74-83.
4. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 1994, 91:1198-1205.
5. Negrier S., Escudier B., Lasset C., Douillard J.Y., Savary J., Chevreau C., Ravaud A., Mercatello A., Peny J., Mousseau M., Philip T., Tursz T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998, 338:1272-1278.
6. Koyama A.H., Arakawa T., Adachi A. Comparison of an antiviral activity of recombinant consensus interferon with recombinant interferon-alpha-2b. Microbes Infect 1999, 1:1073-1077.
7. Blatt L.M., Davis J.M., Klein S.B., Taylor M.W. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996, 16:489-499.
8. Keeffe E., Hollinger F. Consensus interferon study group. Therapy of hepatitis C: consensus interferon trials. Hepatology 1997, 26:101S-107S.
9. Klein M.L., Bartley T.D., Lai P.H., Lu H.S. Structural characterization of recombinant consensus interferon-alpha. J Chromatogr 1988, 454:205-215.
10. Gonzalez S.A. Consensus interferon: tailored therapy and the impact of adherence. Dig Dis Sci 2011, 56:631-634.
11. Alberti A. Interferon alfacon-1: a novel interferon for the treatment of chronic hepatitis C. BioDrugs 1999, 12:343-357.
12. Melian E.B., Plosker G.L. Interferon alfacon-1-a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001, 61:1661-1691.
13. Thitinan S., McConville J.T. Interferon alpha delivery systems for the treatment of hepatitis C. Int J Pharm 2009, 369:121-135.
14. Hisaka T., Yano H., Ogasawara S., Momosaki S., Nishida N., Takemoto Y., Kojiro S., Katafuchi Y., Kojiro M. Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo. J Hepatol 2004, 41:782-789.
15. Ozes O.N., Reiter Z., Klein S., Blatt L.M., Taylor M.W. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992, 12:55-59.
16. Jensen D., Krawitt E.L., Keeffe E., Hollinger F., James S., Mullen K., Everson G., Hoefs J., Fromm H., Black M., Foust R., Pimstone N., Heathcote E., Albert D. Biochemical and viral response to consensus interferon (CIFN) therapy in chronic hepatitis C patients: effect of baseline viral concentration. Consensus interferon study group. Am J Gastroenterol 1999, 94:3583-3588.
17. Sjogren M., Sjogren R., Holtzmuller K., Winston B., Butterfield B., Drake S., Watts A., Howard R., Smith M. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005, 50:727-732.
18. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.
19. Mager D.E., Neuteboom B., Jusko W.J. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 2005, 22:58-61.
20. Du Y., Tian H., Gao X.D., Yao W.B. Pharmacokinetic properties of a 40kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys. Biopharm Drug Dispos 2008, 29:481-484.
21. Pepinsky R.B., LePage D.J., Gill A., Chakraborty A., Vaidyanathan S., Green M., Baker D.P., Whalley E., Hochman P.S., Martin P. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J Pharmacol Exp Ther 2001, 297:1059-1066.
22. Reddy K.R., Wright T.L., Pockros P.J., Shiffman M., Everson G., Reindollar R., Fried M.W., Purdum P.P., Jensen D., Smith C., Lee W.M., Boyer T.D., Lin A., Pedder S., DePamphilis J. Efficacy and safety of pegylated (40-kDa) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001, 33:433-438.
23. Arduini R.M., Li Z., Rapoza A., Gronke R., Hess D.M., Wen D., Miatkowski K., Coots C., Kaffashan A., Viseux N., Delaney J., Domon B., Young C.N., Boynton R., Chen L.L., Chen L., Betzenhauser M., Miller S., Gill A., Pepinsky R.B., Hochman P.S., Baker D.P. Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif 2004, 34:229-242.
24. Baker D.E. Pegylated interferons. Rev Gastroenterol Disord 2001, 1:87-99.
25. Kozlowski A., Charles S.A., Harris J.M. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001, 15:419-429.
26. Ahad M.A., Alim M.A., Ekram Saifuddin A.R.M. Interferon to PEG-interferon: a review. J Teach Assoc 2004, 17:113-116.
27. Glue P., Fang J.W., Rouzier-Panis R., Raffanel C., Sabo R., Gupta S.K., Salfi M., Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C intervention therapy group. Clin Pharmacol Ther 2000, 68:556-567.
28. Rajender Reddy K., Modi M.W., Pedder S. Use of peginterferon alfa-2a (40kDa) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev 2002, 54:571-586.
29. Yang B.B., Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 2011, 50:295-306.
30. Bell S.J., Fam C.M., Chlipala E.A., Carlson S.J., Lee J.I., Rosendahl M.S., Doherty D.H., Cox G.N. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic. Bioconjug Chem 2008, 19:299-305.
31. Kumaki Y., Ennis J., Rahbar R., Turner J.D., Wandersee M.K., Smith A.J., Bailey K.W., Vest Z.G., Madsen J.R., Li J.K., Barnard D.L. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Res 2011, 89:75-82.
32. Cao J., Du Y., Tian H., Gao X.D., Yao W.B. Quantitative determination of pegylated consensus interferon in rhesus monkey serum using a competitive enzyme-linked immunosorbent assay. Immunopharmacol Immunotoxicol 2009, 31:543-549.
33. Fishburn C.S. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008, 97:4167-4183.
34. Fee C.J. Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules. Biotechnol Bioeng 2007, 98:725-731.
35. Hu Z., Niu H., Yang X., Li H., Sang G., Li B. Recombinant human parathyroid hormone 1-34: pharmacokinetics, tissue distribution and excretion in rats. Int J Pharm 2006, 24:144-154.
36. 125I-lidamycin in mice and rats. World J Gastroenterol 2005, 11:3281-3284.
37. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., Graves M. Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001, 12:195-202.
38. Jo Y.W., Youn Y.S., Lee S.H., Kim B.M., Kang S.H., Yoo M., Choi E.C., Lee K.C. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics. Int J Pharm 2006, 309:87-93.
39. Wang Y.S., Youngster S., Grace M., Bausch J., Bordens R., Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002, 54:547-570.